A novel 8-hydroxyquinoline-bridged binuclear ruthenium complex, its synthesis method and application

CN123106770APending Publication Date: 2026-11-17YULIN NORMAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410566161.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-09
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

[0002]癌症是危害人类的最主要的疾病之一,目前钌金属抗癌药物是继铂类临床药物最有希望应用于临床应用的金属抗癌药物之一(Guo, Z.; et al. Chem. Soc. Rev., 2013,42: 202-224.),但是其临床应用还是尚缺,急需开发出新型药物的开发和研究

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of drug development technology, specifically relating to a novel 8-hydroxyquinoline-bridged binuclear ruthenium complex, its synthesis method, and its applications. This invention involves reacting 8-hydroxyquinoline with the metal salt cis-Ru(DMSO)4Cl2 to synthesize four 8-hydroxyquinoline-bridged binuclear ruthenium complexes. These four novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes exhibit low toxicity (>20 µM) to normal HEK293 cells, indicating that they possess tumor-selective inhibitory activity against the drug-resistant human lung cancer cell line A549 / DDP, overcoming resistance to cisplatin in clinical trials. In conclusion, the novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes demonstrate superior antitumor activity and have potential pharmaceutical value, showing promise for the preparation of various antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of drug development technology, specifically relating to a novel 8-hydroxyquinoline-bridged binuclear ruthenium complex, its synthesis method, and its application. Background Technology

[0002] Cancer is one of the most serious diseases threatening human health. Currently, ruthenium metal anticancer drugs are among the most promising metal anticancer drugs for clinical application after platinum-based drugs (Guo, Z.; et al. Chem. Soc. Rev., 2013,42: 202-224.). However, their clinical application is still lacking, and there is an urgent need for the development and research of new drugs.

[0003] In addition, a series of 8-hydroxyquinoline ruthenium anticancer complexes have been reported in the literature (Meng, T.; et al. DaltonTrans., 2019, 48, 5352-5360; Liu, J.; et al., Metallomics, 2014, 6, 518-531.), and studies have found that they have extremely high inhibitory effects on HeLa tumor cells, with an IC50 concentration of 100%. 50 The value was 2.00 ± 0.20 nM; however, research on the effect of 8-hydroxyquinoline-bridged binuclear ruthenium complex on the cisplatin-resistant lung cancer cell line A549 / DDP (LC549) is still lacking.

[0004] Currently, there are no reports on the antitumor effects of novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes with 8-hydroxyquinoline derivatives as active ligands.

[0005] The information disclosed in this background section is intended only to enhance the understanding of the overall background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art known to those skilled in the art. Summary of the Invention

[0006] In view of the shortcomings of the prior art, the purpose of this invention is to provide an antitumor and antibacterial compound and its application.

[0007] The technical solution provided by this invention is as follows:

[0008] A novel 8-hydroxyquinoline-bridged binuclear ruthenium complex, the structural formula of which is as follows:

[0009]

[0010] Where R1 is I, Br, or Cl; and R2 is I, Cl, or Br.

[0011] Preferably, the synthesis method of the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex is as follows: In a 15.0 cm thick-walled drug-resistant tube, weigh 0.2 mmol of 5,7-diiodo-8-hydroxyquinoline (H-QL1a), 5,7-dichloro-8-hydroxyquinoline (H-QL1b), 5-chloro-7-iodo-8-hydroxyquinoline (H-QL1c), and 5,7-dibromo-8-hydroxyquinoline (H-QL1d), and an equal amount of the metal salt cis-Ru(DMSO)4Cl2, respectively. Then add 1.5 mL of CH3OH, 0.5 mL of CH2Cl2, and 0.1 mL of... Triethylamine (Et3N), after being capped with a pressure-resistant tube, was coordinated at 50-90℃ (65℃ being the optimal temperature). After reacting for 72 hours, the mixture was cooled to room temperature, the cap of the system was opened, and a rod-shaped reddish-brown substance was obtained, which is the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex.

[0012] Preferably, the structural formula of the 8-hydroxyquinoline is as follows:

[0013]

[0014] Where R1 is I, Cl, or Br; R2 is I, Cl, or Br.

[0015] This invention also provides the application of the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex in the preparation of antitumor drugs.

[0016] Preferably, the tumor is human lung cancer.

[0017] The present invention also provides an in vitro and in vivo antitumor drug, wherein the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex is used as the active ingredient.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] This invention synthesizes four novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes using 8-hydroxyquinoline as the active ligand and cis-Ru(DMSO)4Cl2 as the metal salt. The activity and toxicity of these complexes against human lung cancer drug-resistant cell line A549 / DDP and normal HEK293 cells were investigated. The results showed that the four novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes effectively inhibited the growth of human lung cancer drug-resistant cell line LC549, with an IC50 concentration of [missing information]. 50The effective values ​​ranged from 12.09 to 19.17 µM, significantly higher than those of H-QL1a–H-QL1d (>20 µM), the metal salt cis-Ru(DMSO)4Cl2 (>20 µM), and the clinical drug cisplatin (>20 µM). The study also found that the four novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes exhibited low toxicity (>20 µM) against normal HEK293 cells, indicating that they possess tumor-selective inhibitory activity against the drug-resistant human lung cancer cell line A549 / DDP, overcoming resistance to clinical cisplatin. In conclusion, the novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes demonstrate superior antitumor activity and have potential pharmaceutical value, holding promise for the preparation of various antitumor drugs. Attached Figure Description

[0020] Figure 1 This is an X-ray single-crystal structure diagram of the complex YNU-4a obtained in Example 1 of the present invention;

[0021] Figure 2 This is an X-ray single crystal structure diagram of the complex YNU-4b obtained in Example 1 of the present invention;

[0022] Figure 3 This is an X-ray single crystal structure diagram of the complex YNU-4c obtained in Example 1 of the present invention;

[0023] Figure 4 This is an X-ray single crystal structure diagram of the complex YNU-4d obtained in Example 1 of the present invention. Detailed Implementation

[0024] The specific embodiments of the present invention will be described in detail below with reference to the examples, but it should be understood that the scope of protection of the present invention is not limited to the specific embodiments.

[0025] Unless otherwise expressly stated, throughout the specification and claims, the term "comprising" or its variations such as "including" or "comprises" shall be understood to include the stated elements or components without excluding other elements or other components.

[0026] Example 1 :

[0027] In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of 5,7-diiodo-8-hydroxyquinoline (H-QL1a), 5,7-dichloro-8-hydroxyquinoline (H-QL1b), 5-chloro-7-iodo-8-hydroxyquinoline (H-QL1c), and 5,7-dibromo-8-hydroxyquinoline (H-QL1d) and an equimolar amount of the metal salt cis-Ru(DMSO)4Cl2 were weighed out, followed by the addition of 1.5 mL CH3OH, 0.5 mL CH2Cl2, and 0.1 mL triethylamine (Et3N). After capping the pressure-resistant tube, coordination was carried out at 65 °C. After reacting for 72 hours, the mixture was cooled to room temperature, the cap was opened, and rod-shaped reddish-brown YNU-4a–YNU-4d were obtained, with yields of 78.6–91.4%.

[0028] The obtained product was identified as follows:

[0029] (1) X-ray single crystal structure diagram of compound YNU-4a–YNU-4d, and its spectrum is shown in Figure 1. Figure 1-4 As shown.

[0030] (2) Elemental analysis results are shown in Table 1.

[0031]

[0032] (3) Infrared spectrum of compound YNU-4a–YNU-4d.

[0033] Data for YNU-4a. Yield: 78.6%. IR (KBr): 3439, 3008, 2917, 1627,1563, 1539, 1480, 1439, 1390, 1368, 1352, 1314, 1294, 1270, 1248, 1220, 1203,1109, 1020, 972, 925, 884, 870, 846, 807, 782, 751, 720, 677, 653, 574, 549,459, 426 cm −1 .

[0034] Data for YNU-4b. Yield: 91.4%. IR (KBr): 3451, 3072, 3013, 2918,2819, 2343, 1968, 1751, 1628, 1579, 1556, 1491, 1448, 1400, 1372, 1359, 1312,1289, 1245, 1222, 1199, 1142, 1115, 1084, 1058, 1015, 976, 932, 892, 884,809, 776, 753, 722, 682, 667, 603, 521, 507, 495, 477, 427 cm −1 .

[0035] Data for YNU-4c. Yield: 83.5%. IR (KBr): 3445, 3077, 3008, 2918,2816, 1750, 1622, 1572, 1553, 1487, 1446, 1395, 1371, 1357, 1314, 1294, 1281,1247, 1219, 1194, 1109, 1054, 1020, 972, 957, 918, 877, 864, 810, 777, 753,720, 692, 662, 678, 587, 498, 469, 427cm −1 .

[0036] Data for YNU-4d. Yield: 80.6%. IR (KBr): 3925, 3435, 3073, 3016,3004, 2926, 1752, 1627, 1574, 1545, 1487, 1440, 1398, 1376, 1359, 1315, 1296,1253, 1218, 1198, 1111, 1090, 1052, 1018, 969, 935, 879, 850, 821, 778, 756,712, 678, 662, 584, 550, 467, 448, 425cm −1 .

[0037] Therefore, the structural formula of the obtained rod-shaped reddish-brown YNU-4a–YNU-4d can be determined as follows:

[0038]

[0039] Example 2 :

[0040] In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of 5,7-diiodo-8-hydroxyquinoline (H-QL1a), 5,7-dichloro-8-hydroxyquinoline (H-QL1b), 5-chloro-7-iodo-8-hydroxyquinoline (H-QL1c), and 5,7-dibromo-8-hydroxyquinoline (H-QL1d) and an equimolar amount of the metal salt cis-Ru(DMSO)4Cl2 were weighed out, followed by the addition of 1.5 mL CH3OH, 0.5 mL CH2Cl2, and 0.1 mL triethylamine (Et3N). After capping the pressure-resistant tube, coordination was carried out at 50 °C. After reacting for 72 hours, the mixture was cooled to room temperature, the cap was opened, and rod-shaped reddish-brown YNU-4a–YNU-4d were obtained, with yields of 78.6–91.4%.

[0041] Example 3 :

[0042] In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of 5,7-diiodo-8-hydroxyquinoline (H-QL1a), 5,7-dichloro-8-hydroxyquinoline (H-QL1b), 5-chloro-7-iodo-8-hydroxyquinoline (H-QL1c), and 5,7-dibromo-8-hydroxyquinoline (H-QL1d) and an equimolar amount of the metal salt cis-Ru(DMSO)4Cl2 were weighed out, followed by the addition of 1.5 mL CH3OH, 0.5 mL CH2Cl2, and 0.1 mL triethylamine (Et3N). After capping the pressure-resistant tube, coordination was carried out at 90 °C. After reacting for 72 hours, the mixture was cooled to room temperature, the cap was opened, and rod-shaped reddish-brown YNU-4a–YNU-4d were obtained, with yields of 78.6–91.4%.

[0043] To fully illustrate the pharmaceutical applications of the four novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes YNU-4a–YNU-4d described in this invention, the applicant conducted in vitro and in vivo antitumor activity experiments on them.

[0044] I. Experimental Study on the Inhibitory Activity of Four Novel 8-Hydroxyquinoline-Bridged Dinuclear Ruthenium Complexes YNU-4a–YNU-4d on Two Human Cell Lines

[0045] 1. Cell lines and cell culture

[0046] This experiment used two human cell lines: A549 / DDP, a drug-resistant human lung cancer cell line, and HEK293, a normal human embryonic kidney cell line.

[0047] All human cell lines were cultured in RPMI-1640 medium containing 100 U / mL penicillin, 10 wt% fetal blood, and 100 U / mL streptomycin, and incubated at 37°C in an incubator containing 5% CO2 by volume.

[0048] 2. Preparation of the test compound

[0049] All compounds YNU-4a–YNU-4d used must have a purity of ≥95%. Their DMSO stock solutions were diluted with physiological buffer to a final solution of 20 mmol / L (final DMSO concentration ≤1%), and the inhibitory effect of each compound on the growth of normal cells or selected tumor cells at this concentration was tested.

[0050] 3. Cell growth inhibition assay (CCK-8 assay)

[0051] (1) Cells were digested, counted, and prepared to a concentration of 5×10⁻⁶. 4 Add 100 μL of cell suspension per well to each well of a 96-well cell culture plate; incubate the 96-well cell culture plate at 37°C in a 5% CO2 incubator for 24 h.

[0052] (2) Dilute the drug to the required concentration with RPMI-1640 medium, add 100 μL of the corresponding drug-containing medium to each well of the 96-well plate, so that the final concentrations reach 0, 1.0, 2.5, 5.0, 10.0 and 20.0 μM respectively. Set up 6 parallel experiments for each concentration. After adding the drug, place the 96-well cell culture plate in a 37℃, 5% CO2 incubator for 48 h.

[0053] (3) Perform CCK-8 staining at λ=450 nm and measure the OD value: Add 10 μL of CCK-8 to each well and continue incubation for 2 h; gently mix on a shaker for 10 min; read the OD value of each well at a wavelength of λ=450 nm using a microplate reader and calculate the inhibition rate. Use the formula:

[0054]

[0055] The inhibition rate of each compound on the growth of the selected cells was calculated, and then the IC50 of each tested compound on each selected cell line was calculated using the Bliss method. 50 The values ​​are shown in Table 2 below.

[0056]

[0057] From Table 2 IC 50 Based on the activity screening results, YNU-4a–YNU-4d effectively promoted the growth of the drug-resistant human lung cancer cell line A549 / DDP, with an IC50 concentration of 100%.50 The values ​​were 19.17±0.89, 12.09±0.53, 15.24±0.70 and 18.04±1.33 µM, respectively, which were much greater than those of H-QL1a–H-QL1d (>20 µM), the metal salt cis-Ru(DMSO)4Cl2 (>20 µM) and the clinical drug cisplatin (>20 µM). The study also found that YNU-4a–YNU-4d had very low toxicity to normal HEK293 cells (>20 µM), indicating that the complex YNU-4a–YNU-4d has a tumor-selective inhibitory effect on the human lung cancer drug-resistant cell line A549 / DDP and overcomes the drug resistance of clinical cisplatin.

[0058] In summary, the four novel 8-hydroxyquinoline-bridged binuclear ruthenium complexes YNU-4a–YNU-4d exhibit superior antitumor activity and have potential pharmaceutical value, and are expected to be used in the preparation of various antitumor drugs.

[0059] The foregoing description of specific exemplary embodiments of the invention is for illustrative and explanatory purposes. These descriptions are not intended to limit the invention to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the foregoing teachings. The exemplary embodiments were chosen and described in order to explain the specific principles of the invention and its practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the invention, as well as various different choices and variations. The scope of the invention is intended to be defined by the claims and their equivalents.

Claims

1. A novel 8-hydroxyquinoline-bridged binuclear ruthenium complex, characterized in that, The structural formula of the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex is as follows: Where R1 is I, Br, or Cl; and R2 is I, Cl, or Br.

2. The novel 8-hydroxyquinoline-bridged binuclear ruthenium complex according to claim 1, characterized in that, The synthesis method of the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex is as follows: In a 15.0 cm thick-walled drug-resistant tube, 0.2 mmol of 5,7-diiodo-8-hydroxyquinoline (H-QL1a), 5,7-dichloro-8-hydroxyquinoline (H-QL1b), 5-chloro-7-iodo-8-hydroxyquinoline (H-QL1c), and 5,7-dibromo-8-hydroxyquinoline (H-QL1d), and an equal amount of the metal salt cis-Ru(DMSO)4Cl2 were weighed out, followed by the addition of 1.5 mL CH3OH, 0.5 mL CH2Cl2, and 0.1 mL... Triethylamine (Et3N), after being capped with a pressure-resistant tube, was coordinated at 50-90℃ (65℃ being the optimal temperature). After reacting for 72 hours, the mixture was cooled to room temperature, the cap of the system was opened, and a rod-shaped reddish-brown substance was obtained, which is the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex.

3. The novel 8-hydroxyquinoline-bridged binuclear ruthenium complex according to claim 2, characterized in that, The structural formula of the 8-hydroxyquinoline is as follows: Where R1 is I, Cl, or Br; R2 is I, Cl, or Br.

4. The application of the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex according to claim 1 in the preparation of antitumor drugs.

5. The application according to claim 4, characterized in that, The tumor is human lung cancer.

6. An in vitro and in vivo antitumor drug, characterized in that, The in vitro and in vivo antitumor drug uses the novel 8-hydroxyquinoline-bridged binuclear ruthenium complex as described in claim 1 as its active ingredient.